• news.cision.com/
  • RLS Global AB/
  • Further progress with ChloraSolv[®] roll out across Europe – market access activities in the Netherlands signal positive momentum

Further progress with ChloraSolv[®] roll out across Europe – market access activities in the Netherlands signal positive momentum

Report this content

RLS Global, a medical healthcare company based in Sweden, and ConvaTec, one of the world’s leading advanced wound care companies, have made continued progress with the distribution and commercialisation of ChloraSolv®, a ground-breaking gentle wound debrider, in Europe.

After intensive market preparation and work with specialist wound experts in the Netherlands, ChloraSolv® gel was listed on January 1, 2022 in the Z- index and received a positive recommendation for reimbursement from Zorginstituut Nederland (ZN).

Chlorasolv® is already available in other European markets such as the Nordic countries.

Karin Fischer, CEO, RLS Global, said:
“I am very pleased with the registration and positive reimbursement recommendation achieved in the Netherlands. Together with ConvaTec we are focused on accelerating the activities to achieve reimbursement across key European markets”.

Sandrine Letellier, VP Global Marketing for ConvaTec Advanced Wound Care, said:
“At ConvaTec we’re focused on pioneering trusted medical solutions to improve the lives we touch. Effective debridement is a key step within our Wound HygieneTM Protocol of Care and ChloraSolv® brings a new gentle yet effective solution for the management of diabetic foot ulcers (DFUs) and venous leg ulcers (VLUs). We shall continue to invest in generating robust clinical and health economic data to illustrate the value we feel the product brings to patients”.

ChloraSolv®, manufactured by RLS Global, is a CE marked wound bed preparation gel intended for cleansing and debridement of the wound1. Without damaging the healthy tissue, ChloraSolv® ensures fast and easy debridement by softening and making it easy to mechanically remove devitalized tissue, pus and other biological debris that prevents the wound from healing2,3.

  1. ChloraSolv® instructions for use.
  2. Berqvist K, Almhöjd U, Herrmann I, Eliasson B. The role of chloramines in treatment of diabetic foot ulcers: an exploratory multicentre randomised controlled trial. Clinical Diabetes and Endocrinology; 2016 2:6
  3. Eliasson B, Fagerdahl A, Jönsson A, Apelqvist J. Debriding effect of amino acid-buffered hypochlorite on hard-to-heal wounds covered by devitalised tissue: pilot study. Journal of Wound Care; 2021 30:6;​

RLS Global’s shares have been listed on the Nasdaq First North Growth Market since 17th May, 2017 and trading takes place under the short name RLS. Certified Adviser is Redeye Aktiebolag, phone: +46 8 121 576 90, email: certifiedadviser@redeye.se. During the period 2012–2017, the company was listed on Aktietorget.

Karin Fischer, CEO, RLS Global
E-mail: karin.fischer@rlsglobal.se
Tel: +46 702 48 46 51

Sandrine Lettelier, Vice President Global Marketing, ConvaTec Advanced Wound Care
E-mail: sandrine.letellier@convatec.com

About RLS Global AB
RLS Global AB is a medical technology company within Life Science. Based on the company's unique hypochlorite platform, RLS Global develop products for some of our most common illnesses in wound and oral care. RLS Global has a portfolio of strong brands, including ChloraSolv® and Carisolv®. RLS’ long-term vision is to be a leading research driven platform company in wound care. The ambition is to expand into new indications through new research and development projects in areas such as burns and dermatology. In order to maximize our patient reach, RLS intends to work with partners to commercialize its products globally. RLS is confident in the company’s platform technology and its unique features and what this can bring to patients around the world. Read more at www.rls.global

About ConvaTec
ConvaTec is a FTSE 250 global medical products and technologies company focused on solutions for the management of chronic conditions, with leading market positions in advanced wound care, ostomy care, continence and critical care, and infusion care. The company has more than 10,000 employees and operate in over 100 countries. ConvaTec's vision is pioneering trusted medical solutions to improve the lives we touch. ConvaTec's products provide a range of clinical and economic benefits including infection prevention, protection of at-risk skin, improved patient outcomes and reduced total cost of care. Group revenues in 2020 were over $1.894 billion. To learn more about ConvaTec, please visit www.convatecgroup.com